jay keasling professorambiguous chemical engineering bioengineering university california also associate laboratory director biosciences lawrence berkeley national laboratory chief executive officer joint bioenergy considered one foremost authorities synthetic biology especially field metabolic engineering keasling elected member national academy engineering developing synthetic biology tools engineer antimalarial drug artemisinin keasling received bachelors degree university nebraskalincoln member delta tau delta international fraternity went complete doctor philosophy degree university michigan supervision bernhard keasling performed postdoctoral research arthur kornberg stanford university keaslings currentwhen focused engineering chemistry inside microorganisms area known metabolic engineering production useful chemicals environmental cleanup much way synthetic organic industrial chemistry allowed chemists chemical engineers produce fossil fuel resources chemicals use every day metabolic engineering revolutionize production useful chemicals renewable resources like sugar cellulosic biomass many years work metabolic engineering limited lack enzymes perform necessary chemistry tools manipulate monitor chemistry inside cells seeing need better genetic tools keasling began working genetic tool development area known synthetic biology keasling laboratory developed adopted many latest analytical tools troubleshoot genetic manipulations keaslings laboratory applied metabolic chemistry number realworld problems including production antimalarial drug artemisinin dropin biofuels keasling published papers peerreviewed journals issued patents malaria global health problem threatens million people kills one million people annually chloroquinebased drugs used widely past lost effectiveness plasmodium parasite causes malaria become resistant artemisinin sesquiterpene lactone endoperoxide extracted artemisia annua l highly effective plasmodium spp resistant antimalarial drugs however several problems current production methods artemisinin first artemisinin combination therapies acts expensive people developing world second artemisinin extracted annua yield consistency depend climate extraction process method chemical synthesis artemisinin low yielding therefore expensive use producing lowcost drugs third although world health organization recommended artemisinin formulated active pharmaceutical ingredients acts many manufacturers still producing monotherapies artemisinin increase chance plasmodium spp develop resistance artemisinin keaslings laboratory university california berkeley engineered escherichia coli saccharomyces cerevisiae produce artemisinic acid precursor artemisinin derivatized using established simple inexpensive chemistry form artemisinin artemisinin derivative currently used treat microorganisms engineered tenenzyme biosynthetic pathway using genes artemisia annua saccharomyces cerevisiae escherichia coli twelve genes transform simple renewable sugar like glucose complicated chemical structure antimalarial drug artemisinin engineered microorganism capable secreting final product cell thereby purifying intracellular chemicals reducing purification costs therefore cost final drug given existence known relatively highyielding chemistry conversion artemisinic acid artemisinin artemisinin derivative microbiallyproduced artemisinic acid viable renewable scalable source potent family antimalarial critical element keaslings work development genetic tools aid manipulation microbial metabolism particularly lowvalue products require high yields sugarhis laboratory developed singlecopy plasmids expression complex metabolic pathways promoter systems allow regulated control transcription consistently cells culture mrna stabilization technologies regulate stability mrna protein engineering approach attach several enzymes metabolic pathway onto synthetic protein scaffold increase pathway gene expression tools enable precise control expression genes encode novel metabolic pathways maximize chemical production minimize losses side products minimize accumulation toxic intermediates may poison microbial host important economical production important drug another critical aspect keaslings work discovering chemistry enzymes artemisia annua responsible synthesis enzymes included cytochrome oxidizes amorphadiene artemisinic acid redox partners transfer reducing equivalents enzyme cofactors discovery enzymes functional expression yeast e coli along nine enzymes metabolic pathway allowed production artemisinic acid two cerevisiae chosen largescale production process engineered improve artemisinic acid keaslings microbial production process number advantages extraction plants first microbial synthesis reduce cost artemisinin expensive component artemisininbased combination much therefore make artemisininderived antimalarial drugs affordable people developing world second weather conditions political climates might otherwise affect yield cost plantderived version drug affect microbial source drug third microbial production artemisinin large tanks allow careful distribution artemisinin legitimate drug manufacturers formulate artemisinin combination therapies rather monotherapies turn slow development resistance drug fourth severe shortages plantderived artemisinin projected beyond increase cost artemisinin combination therapies finally microbiallyderived artemisinic acid enable production new derivatives artemisinin plasmodium may resistant thereby extending time artemisinin may used ensure process developed would benefit people developing world keasling assembled unique team consisting laboratory university california berkeley amyris biotechnologies company founded technology institute oneworld health nonprofit pharmaceutical company located san francisco addition assembling team keasling developed intellectual property model ensure microbiallysourced artemisinin could offered inexpensively possible people developing world patents granted work ucb licensed royalty free amyris biotechnologies institute oneworld health use producing artemisinin long make profit artemisinin sold developing world team funded december bill melinda gates foundation develop microbial production process science completed december sanofiaventis licensed technology worked amyris develop production process sanofiaventis produced tonswhen artemisinin using keasling microbial production process enough million treatments distribution artemisinin combination therapies containing microbiallysourced artemisinin began august million treatments shipped africa anticipated million treatments produced using technology shipped annually africa asia south america renewable fuels needed modes transportation microbiallysourced fuels used small fraction gasoline conventional sparkignition engines keasling laboratory engineered microorganisms produce hydrocarbons similar properties fuels derived petroleum fuels synthesized plantderived sugars cellulose feedstock little economic value consequently microbes minimize carbon footprint minimizing energy expenditure sourcing fuel offshore drilling hydraulic fracturing keasling colleagues demonstrated escherichia coli saccharomyces cerevisiae engineered produce fatty acidbased biofuels fatty acid ethyl methyl linear hydrocarbons key components diesel biologically produced fuels excellent diesel replacements however fuels containing long linear hydrocarbon chains freeze cold conditions develop fuels suitable cold applications keaslings laboratory engineered e coli cerevisiae produce branched cyclic hydrocarbons using isoprenoid biosynthetic pathway isopentanol dropin replacement pinene replacement jet bisabolene replacement diesel isoprenoids add methyl side chain every four carbons backbone fuels made isoprenoids low freeze cloud points making suitable coldweather diesels jet fuels one biggest challenges scaling microbial fermentations stability microbial strain engineered microorganism attempt mutate shed metabolic pathway part intermediates metabolic pathway accumulate toxic cells balance pathway flux reduce cost producing desired biofuel keaslings laboratory developed dynamic regulators sense levels intermediates pathway regulate pathway regulators stabilized pathway cell improved biofuel yields making possible grow engineered cells largescale fermentation tanks fuel production many best fuels chemicals toxic producer organism one way limit fuel toxicity actively pump fuel cell identify pumps ideally suited particular fuel keasling colleagues bioprospected environmental microorganisms many different threecomponent transporters selected pumps effective particular transporters allowed e coli grow presence fuels result produce target fuel would able absence transporter starting materials generally sugars significant factor biofuel production cost cellulose potentially lowcost starting material must depolymerized sugars adding expensive cocktail enzymes one way reduce cost engineer fuelproducing microbe also produce enzymes depolymerize cellulose hemicellulose recently keaslings laboratory demonstrated microorganism could engineered synthesize secrete enzymes depolymerize cellulose hemicellulose sugars produce gasoline replacement butanol dieselfuel replacement fatty acid ethyl ester jet fuel replacement technological platform biofuel manufacturing faces huge economic hurdles many depend market pricing crude oil conventionally sourced fuels nonetheless metabolic engineering technology becoming increasingly competitive expected widereaching effects keasling founder amyris vincent martin jack newman neil renninger kinkead reiling part reg george church chris sommerville lygos leonard katz clem fortman jeffrey dietrich eric steen keasling originally harvard nebraska openly httpsenwikipediaorgwikijaykeasling